These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 34283088)

  • 1. Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation.
    Zheng H; Siddharth S; Parida S; Wu X; Sharma D
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer.
    Deepak KGK; Vempati R; Nagaraju GP; Dasari VR; S N; Rao DN; Malla RR
    Pharmacol Res; 2020 Mar; 153():104683. PubMed ID: 32050092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis.
    Malla RR; Vasudevaraju P; Vempati RK; Rakshmitha M; Merchant N; Nagaraju GP
    Cancer; 2022 Mar; 128(6):1171-1183. PubMed ID: 34990009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
    Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
    Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment.
    Adinew GM; Taka E; Mochona B; Badisa RB; Mazzio EA; Elhag R; Soliman KFA
    Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
    Qattan A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting.
    Furukawa N; Stearns V; Santa-Maria CA; Popel AS
    Expert Opin Ther Targets; 2022 Dec; 26(12):1041-1056. PubMed ID: 36657483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenic Cell Death-Relevant Damage-Associated Molecular Patterns and Sensing Receptors in Triple-Negative Breast Cancer Molecular Subtypes and Implications for Immunotherapy.
    Xu M; Lu JH; Zhong YZ; Jiang J; Shen YZ; Su JY; Lin SY
    Front Oncol; 2022; 12():870914. PubMed ID: 35444934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted Non-Coding RNAs: Functional Impact on the Tumor Microenvironment and Clinical Relevance in Triple-Negative Breast Cancer.
    Di Agostino S; Vahabi M; Turco C; Fontemaggi G
    Noncoding RNA; 2022 Jan; 8(1):. PubMed ID: 35076579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.
    Bareche Y; Buisseret L; Gruosso T; Girard E; Venet D; Dupont F; Desmedt C; Larsimont D; Park M; Rothé F; Stagg J; Sotiriou C
    J Natl Cancer Inst; 2020 Jul; 112(7):708-719. PubMed ID: 31665482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
    Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
    Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy.
    Wang G; Yao Y; Huang H; Zhou J; Ni C
    Front Oncol; 2023; 13():1131259. PubMed ID: 37284197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative analysis identifies cancer cell-intrinsic RARRES1 as a predictor of prognosis and immune response in triple-negative breast cancer.
    Yu Z; Liu H; Ye J; Liu Y; Xin L; Liu Q; Cheng Y; Yin L; Xu L
    Front Genet; 2024; 15():1360507. PubMed ID: 38533207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
    Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
    Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferroptosis: the emerging player in remodeling triple-negative breast cancer.
    Li J; He D; Li S; Xiao J; Zhu Z
    Front Immunol; 2023; 14():1284057. PubMed ID: 37928550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
    Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
    J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
    Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
    Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors.
    Naik A; Decock J
    Front Oncol; 2020; 10():598626. PubMed ID: 33324565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Tumor Microenvironment: Emerging target of therapeutic phytochemicals.
    Malla RR; Deepak K; Merchant N; Dasari VR
    Phytomedicine; 2020 Apr; 70():153227. PubMed ID: 32339885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.